Breaking News Instant updates and real-time market news.

GEMP

Gemphire Therapeutics

$9.70

0.1 (1.04%)

11:12
11/28/16
11/28
11:12
11/28/16
11:12

Gemphire Therapeutics enrolls first patient in ROYAL-1 trial

Gemphire Therapeutics announced enrollment of its first patients in ROYAL-1, a Phase 2b trial designed to investigate gemcabene in the treatment of patients with hypercholesterolemia not adequately controlled on high-intensity or moderate-intensity stable statin therapy. It is designed to enroll a broad patient population, including patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease, who have baseline LDL-C, or "bad cholesterol," values greater than or equal to 100 mg/dL. The randomized, placebo-controlled, double-blind Phase 2b trial, "A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins," will enroll up to 104 adult patients at clinical sites in the United States. Patients meeting eligibility requirements are being randomized in a 1:1 ratio to 600mg of gemcabene or placebo. The primary endpoint is the percent change from baseline of LDL-C at 12 weeks. Secondary endpoints include the change from baseline in non-HDL-C, total cholesterol, triglycerides, ApoB, and hsCRP at the 12-week time point. Gemphire currently anticipates the 12-week study to complete enrollment and all patient follow-up visits in the second half of 2017. The company re-issued its initial press release to correct that in the original the phrase "The open-label" should have read "The randomized, placebo-controlled, double-blind".

  • 06

    Dec

GEMP Gemphire Therapeutics
$9.70

0.1 (1.04%)

08/30/16
JEFF
08/30/16
INITIATION
Target $15
JEFF
Buy
Gemphire Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Matthew Andrews started Gemphire Therapeutics with a Buy rating and $15 price target. The company's gemcabene has a favorable profile in the broad dyslipidemia market, Andrews tells investors in a research note.
08/30/16
ADAM
08/30/16
INITIATION
Target $17
ADAM
Buy
Gemphire Therapeutics initiated with a Buy at Canaccord
Canaccord Genuity analyst John Newman started Gemphire Therapeutics with a Buy rating and $17 price target. The company's oral cholesterol drug gemcabene has a $2.8B U.S. peak market potential, Newman tells investors in a research note.
08/30/16
RBCM
08/30/16
INITIATION
Target $25
RBCM
Outperform
Gemphire Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Adnan Butt started Gemphire Therapeutics with an Outperform rating and $25 price target.
08/30/16
08/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BofA Merrill Lynch resumed coverage on Hershey (HSY) with an Underperform rating and $100 price target, as the firm expects shares to trade on fundamentals, which are under pressure. Last night, Mondelez (MDLZ) announced it has ended discussions with Hershey regarding a possible combination of the two companies. 2. eBay (EBAY) initiated with a Long-Term Buy at Hilliard Lyons by analyst Stephen Turner , who set a $35 price target on the stock. 3. Galapagos NV (GLPG) initiated with a Buy at Janney Capital by Debjit Chattopadhyay, who said that filgotinib, the company's oral JAK inhibitor, is "shaping up to be a blockbuster." 4. Gemphire Therapeutics (GEMP) initiated with with a Buy rating and $17 price target by Canaccord Genuity analyst John Newman and with a Buy rating and $15 price target by Jefferies analyst Matthew Andrews. 5. Sophiris Bio (SPHS) initiated with an an Overweight rating and $7 price target by Piper Jaffray analyst Charles Duncan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

CBS

CBS

$61.15

0.97 (1.61%)

13:40
12/05/16
12/05
13:40
12/05/16
13:40
Hot Stocks
CBS CEO: Company targeting stock price of $100 by 2020 »

Says All Access, Showtime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 12

    Dec

NVS

Novartis

$69.05

0.8846 (1.30%)

13:40
12/05/16
12/05
13:40
12/05/16
13:40
Hot Stocks
Novartis reports new data from Tasigna ENESTop study »

Novartis announced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

13:40
12/05/16
12/05
13:40
12/05/16
13:40
General news
U.S. equities are below earlier highs »

U.S. equities are below…

TOL

Toll Brothers

$30.09

0.77 (2.63%)

13:38
12/05/16
12/05
13:38
12/05/16
13:38
Technical Analysis
Toll Brothers technical comments before earnings, potential bullish pattern »

There is a potential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

13:35
12/05/16
12/05
13:35
12/05/16
13:35
General news
NY Fed's overnight reverse repo totaled $168.4 B, with 51 counterparties »

NY Fed's overnight…

FTI

FMC Technologies

$36.35

0.75 (2.11%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

13:31
12/05/16
12/05
13:31
12/05/16
13:31
Hot Stocks
FMC Technologies, Technip shareholders approve business combination »

FMC Technologies (FTI)…

FTI

FMC Technologies

$36.35

0.75 (2.11%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

NVS

Novartis

$69.06

0.89 (1.31%)

13:26
12/05/16
12/05
13:26
12/05/16
13:26
Hot Stocks
Novartis' MPN survey results 'help quantify' daily difficulty of MPN »

Novartis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

AXP

American Express

$72.24

0.38 (0.53%)

13:25
12/05/16
12/05
13:25
12/05/16
13:25
Hot Stocks
Barclays turns focus on American Express toward enterprise strength »

Research firm Barclays…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

CBS

CBS

$61.26

1.075 (1.79%)

, T

AT&T

$38.81

0.2 (0.52%)

13:22
12/05/16
12/05
13:22
12/05/16
13:22
Hot Stocks
CBS CEO: AT&T will not get Showtime for $5 a month »

CBS (CBS) CEO Moonves…

CBS

CBS

$61.26

1.075 (1.79%)

T

AT&T

$38.81

0.2 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

FRBK

Republic First Bancorp

$5.35

-0.05 (-0.93%)

13:22
12/05/16
12/05
13:22
12/05/16
13:22
Hot Stocks
Republic First Bancorp elects Vernon Hill as chairman »

Republic First Bancorp,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$61.25

1.07 (1.78%)

, T

AT&T

$38.79

0.18 (0.47%)

13:20
12/05/16
12/05
13:20
12/05/16
13:20
Hot Stocks
CBS CEO says will make deal with DirecTV online »

CBS (CBS) CEO Leslie…

CBS

CBS

$61.25

1.07 (1.78%)

T

AT&T

$38.79

0.18 (0.47%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

  • 15

    Jan

YUM

Yum! Brands

$63.07

0.65 (1.04%)

13:20
12/05/16
12/05
13:20
12/05/16
13:20
Options
3X average daily option volume in Yum Brands as players gobble up Jan 65 calls »

3X average daily option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CBS

CBS

$61.24

1.055 (1.75%)

, T

AT&T

$38.80

0.185 (0.48%)

13:19
12/05/16
12/05
13:19
12/05/16
13:19
Hot Stocks
CBS CEO says in discussions over DirecTV NOW »

Says industry needs total…

CBS

CBS

$61.24

1.055 (1.75%)

T

AT&T

$38.80

0.185 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

$NYE

NYSE Market Internals

13:16
12/05/16
12/05
13:16
12/05/16
13:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:16
12/05/16
12/05
13:16
12/05/16
13:16
Technical Analysis
NASDAQ market internals summary »

Volume is extremely heavy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

, SNY

Sanofi

$40.79

0.77 (1.92%)

13:15
12/05/16
12/05
13:15
12/05/16
13:15
Hot Stocks
Alnylam 'pleased' with updated ALN-CC5 Phase 1/2 trial results »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

SNY

Sanofi

$40.79

0.77 (1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

DPZ

Domino's Pizza

$168.06

0.06 (0.04%)

13:14
12/05/16
12/05
13:14
12/05/16
13:14
Hot Stocks
Domino's locations throughout Phoenix to hire 300 new team members »

Domino's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Jan

CYNO

Cynosure

$44.35

-0.7 (-1.55%)

13:11
12/05/16
12/05
13:11
12/05/16
13:11
Conference/Events
Cynosure management to meet with Maxim »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

13:11
12/05/16
12/05
13:11
12/05/16
13:11
Hot Stocks
Global Blood Therapeutics announces details on PRO tool in phase 3 HOPE study »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CBS

CBS

$61.09

0.905 (1.50%)

, NFLX

Netflix

$120.81

3.59 (3.06%)

13:11
12/05/16
12/05
13:11
12/05/16
13:11
Hot Stocks
CBS' Moonves: 2017 will be 'very strong year' for company »

CBS (CBS) CEO Moonves…

CBS

CBS

$61.09

0.905 (1.50%)

NFLX

Netflix

$120.81

3.59 (3.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 12

    Dec

CSIQ

Canadian Solar

$11.07

-0.21 (-1.86%)

13:10
12/05/16
12/05
13:10
12/05/16
13:10
Options
Calls active in Canadian Solar as shares see relative strength »

Calls active in Canadian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

COST

Costco

$152.09

0.35 (0.23%)

13:08
12/05/16
12/05
13:08
12/05/16
13:08
Periodicals
Ontario regulator investigating Costco allegations, STAT reports »

Ontario's Ministry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

13:07
12/05/16
12/05
13:07
12/05/16
13:07
Hot Stocks
Seattle Gen.: Patients in ADCETRIS trial achieve significant durable remissions »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SMCI

Super Micro Computer

$27.00

0.8 (3.05%)

13:07
12/05/16
12/05
13:07
12/05/16
13:07
Conference/Events
Super Micro Computer management to meet with Maxim »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 08

    Feb

  • 09

    Feb

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

13:04
12/05/16
12/05
13:04
12/05/16
13:04
Hot Stocks
Juno announces 'encouraging' preliminary JCAR017 clinical data for NHL patients »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.